Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Inventory: 2018-2024

Historic Change in Inventory for Coherus Oncology (CHRS) over the last 7 years, with Dec 2024 value amounting to $32.0 million.

  • Coherus Oncology's Change in Inventory fell 135.72% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year decrease of 39.81%. This contributed to the annual value of $32.0 million for FY2024, which is 31.63% down from last year.
  • Per Coherus Oncology's latest filing, its Change in Inventory stood at $32.0 million for FY2024, which was down 31.63% from $46.7 million recorded in FY2023.
  • Coherus Oncology's Change in Inventory's 5-year high stood at $47.3 million during FY2022, with a 5-year trough of $6.3 million in FY2021.
  • Moreover, its 3-year median value for Change in Inventory was $46.7 million (2023), whereas its average is $42.0 million.
  • As far as peak fluctuations go, Coherus Oncology's Change in Inventory crashed by 83.70% in 2021, and later soared by 657.20% in 2022.
  • Over the past 5 years, Coherus Oncology's Change in Inventory (Yearly) stood at $38.4 million in 2020, then slumped by 83.70% to $6.3 million in 2021, then surged by 657.20% to $47.3 million in 2022, then dropped by 1.30% to $46.7 million in 2023, then slumped by 31.63% to $32.0 million in 2024.